Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Taxes (2018 - 2024)

Inmune Bio (INMB) has disclosed Change in Taxes for 6 consecutive years, with $20000.0 as the latest value for Q1 2024.

  • Quarterly Change in Taxes fell 41.18% to $20000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2024, down 31.12% year-over-year, with the annual reading at $175000.0 for FY2023, 176.42% up from the prior year.
  • Change in Taxes hit $20000.0 in Q1 2024 for Inmune Bio, down from $34000.0 in the prior quarter.
  • In the past five years, Change in Taxes ranged from a high of $1.9 million in Q3 2021 to a low of -$45000.0 in Q4 2021.
  • Historically, Change in Taxes has averaged $439900.0 across 4 years, with a median of $276500.0 in 2020.
  • Biggest five-year swings in Change in Taxes: surged 972.8% in 2020 and later tumbled 120.36% in 2021.
  • Year by year, Change in Taxes stood at $221000.0 in 2020, then crashed by 120.36% to -$45000.0 in 2021, then surged by 175.56% to $34000.0 in 2023, then crashed by 41.18% to $20000.0 in 2024.
  • Business Quant data shows Change in Taxes for INMB at $20000.0 in Q1 2024, $34000.0 in Q1 2023, and -$45000.0 in Q4 2021.